AtheroGenics releases diabetes data

AtheroGenics has released Phase III trial data showing that the patients who did not have diabetes when beginning treatment and assigned to the AGI-1067 dosage group benefited by a 63 percent reduction in progression to new onset diabetes, compared to the patients receiving placebo. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.